Published in Health Aff (Millwood) on March 10, 2005
Return of Actionable Variants Empirical Study (RAVE) | NCT03640234
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) (2010) 1.67
The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials (2014) 1.62
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
Debating clinical utility. Public Health Genomics (2010) 1.41
The future of direct-to-consumer clinical genetic tests. Nat Rev Genet (2011) 1.38
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol (2009) 1.37
Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics. Clin Genet (2011) 1.34
Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet (2013) 1.33
Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics (2010) 1.22
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers (2011) 1.06
GINA, genism, and civil rights. Bioethics (2008) 1.02
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement (2008) 1.00
The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet (2010) 0.98
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol (2013) 0.98
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
The ghost in our genes: legal and ethical implications of epigenetics. Health Matrix Clevel (2009) 0.97
The right not to know: the case of psychiatric disorders. J Med Ethics (2011) 0.97
Emerging issues in public health genomics. Annu Rev Genomics Hum Genet (2014) 0.91
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med (2011) 0.90
Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. J Genet Couns (2011) 0.89
Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther (2013) 0.89
Ethical issues of predictive genetic testing for diabetes. J Diabetes Sci Technol (2009) 0.89
Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun (2009) 0.87
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. Genet Med (2010) 0.86
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol (2010) 0.81
Health insurance and the Genetic Information Nondiscrimination Act of 2008: implications for public health policy and practice. Public Health Rep (2009) 0.79
Associations between self-referral and health behavior responses to genetic risk information. Genome Med (2015) 0.76
Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther (2016) 0.76
Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study. Alzheimers Res Ther (2016) 0.75
Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment? Int J Alzheimers Dis (2010) 0.75
Engagement and communication among participants in the ClinSeq Genomic Sequencing Study. Genet Med (2016) 0.75
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Discrimination as a consequence of genetic testing. Am J Hum Genet (1992) 10.40
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med (2004) 2.44
Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol (1994) 2.24
Genetic discrimination: perspectives of consumers. Science (1996) 2.13
Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology (1996) 1.85
Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A (2003) 1.33
Insurance underwriting in the genetic era. Am J Hum Genet (1997) 1.10
Genetic testing, adverse selection, and the demand for life insurance. Am J Med Genet (2000) 1.04
Experiences and attitudes concerning genetic testing and insurance in a Colorado population: a survey of families diagnosed with fragile X syndrome. Am J Med Genet (1996) 0.98
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Broad Consent for Research With Biological Samples: Workshop Conclusions. Am J Bioeth (2015) 8.99
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 5.55
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci (2004) 3.73
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res (2012) 2.76
Point-counterpoint. Ethics and genomic incidental findings. Science (2013) 2.73
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med (2004) 2.44
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Racial and ethnic differences in direct-to-consumer genetic tests awareness in HINTS 2007: sociodemographic and numeracy correlates. J Genet Couns (2012) 2.25
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn (2013) 2.03
Direct to consumer genetic testing: Avoiding a culture war. Genet Med (2009) 2.00
DNA patents and diagnostics: not a pretty picture. Nat Biotechnol (2010) 1.95
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Methodological Considerations in Studying Centenarians: Lessons Learned From the Georgia Centenarian Studies. Annu Rev Gerontol Geriatr (2007) 1.85
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry (2011) 1.83
Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.79
Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol (2006) 1.78
Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. Arch Clin Neuropsychol (2008) 1.69
Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) (2010) 1.67
Successful aging in the United States: prevalence estimates from a national sample of older adults. J Gerontol B Psychol Sci Soc Sci (2009) 1.64
Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology (2013) 1.63
The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials (2014) 1.62
The effects of business practices, licensing, and intellectual property on development and dissemination of the polymerase chain reaction: case study. J Biomed Discov Collab (2006) 1.54
Ethical and practical issues associated with aggregating databases. PLoS Med (2008) 1.53
Regulation: The FDA is overcautious on consumer genomics. Nature (2014) 1.52
Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry (2007) 1.50
Metastasizing patent claims on BRCA1. Genomics (2010) 1.48
Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med (2016) 1.47
Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care (2012) 1.46
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
The future of direct-to-consumer clinical genetic tests. Nat Rev Genet (2011) 1.38
Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol (2002) 1.37
Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Genet Med (2010) 1.36
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement (2011) 1.35
The adult galactosemic phenotype. J Inherit Metab Dis (2011) 1.34
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol (2013) 1.33
Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci (2009) 1.33
Clock drawing test ratings by dementia specialists: interrater reliability and diagnostic accuracy. J Neuropsychiatry Clin Neurosci (2010) 1.33
Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet (2013) 1.33
A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol (2011) 1.33
Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev (2011) 1.32
Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease. Genet Med (2010) 1.30
Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril (2008) 1.30
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns (2006) 1.26
Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Arch Clin Neuropsychol (2006) 1.26
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26
Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet (2011) 1.25
Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr (2010) 1.25
Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal (2005) 1.25
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.21
"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med (2010) 1.19
Lower-extremity function in cognitively healthy aging, mild cognitive impairment, and Alzheimer's disease. Arch Phys Med Rehabil (2010) 1.18
Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med (2005) 1.17
The beliefs, motivations, and expectations of parents who have enrolled their children in a genetic biorepository. Genet Med (2012) 1.17
Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test (2003) 1.16
Direct-to-consumer genetic testing: an assessment of genetic counselors' knowledge and beliefs. Genet Med (2011) 1.16
Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol (2008) 1.16
A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord (2009) 1.16
A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Med Genet (2014) 1.14
Health-care referrals from direct-to-consumer genetic testing. Genet Test Mol Biomarkers (2010) 1.13
Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing. Genet Med (2012) 1.11
Is Bayh-Dole good for developing countries? Lessons from the US experience. PLoS Biol (2008) 1.09
Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet (2005) 1.08
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med (2008) 1.08